ExonHit Therapeutics, Phase 2 clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease

20 December 2007 - ExonHit Therapeutics, a drug and diagnostic discovery company, announced today that it has obtained a regulatory approval to initiate a Phase 2 clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease. EHT 0202 is a compound, with a novel mechanism of action, which has shown benefits on memory and neuronal loss... ExonHit's Press Release -

AstraZeneca and Banner Alzheimer's Institute, collaboration to evaluate new tool targeting Alzheimer's disease

December 19, 2007 — The Banner Alzheimer’s Institute and AstraZeneca (NYSE:AZN) announced that they will collaborate to help advance understanding of Alzheimer’s disease and increase knowledge of potential new avenues for treatment through the use of cutting-edge brain imaging methods. The new alliance will focus on the evaluation and further development of a radioligand discovered by AstraZeneca. This radioligand is a molecule that binds to amyloid plaque — protein deposits in the brain that are a hallmark of Alzheimer’s disease — and allows the plaque to be measured in real time using a positron emission tomography (PET) scan... The Banner Alzheimer’s Institute's Press Release -

GlaxoSmithKline, neuroscience pipeline with compound 742457 for Alzheimer’s disease

Thursday 13 December 2007 - ...742457 — A novel treatment to delay the symptoms of Alzheimer’s disease : Alzheimer’s disease is a devastating neurological condition, with significant consequences on the quality of life for sufferers and their care givers. GSK has a broad programme of research ongoing in Alzheimer’s disease, including 742457, a novel treatment that selectively targets the 5HT6 receptors concentrated within the brain. These receptors are associated with learning and memory... GSK's Press Release -

Samaritan, Favorable Caprospinol Data At Alzheimer's Drug Development Summit

November 27, 2007 - ...In an in vivo 'Proof of Concept' study, Samaritan Pharmaceuticals, Inc. has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in vitro data and suggests Caprospinol may not only slow the progress of Alzheimer's , but may also reverse plaque-related brain injuries associated with the disease. The rats tested with the company's proprietary Alzheimer's rat model took on features similar to the crippling signs of dementia seen in human patients suffering from Alzheimer's; by treating the rats with Caprospinol, the rat's brain cells regained complete memory... Samaritan's Press Release -

BioArctic Neuroscience and Eisai, Agreement with Novel Antibody Treatment for Alzheimer’s Disease

December 3rd 2007. The Swedish biopharmaceutical company BioArctic Neuroscience AB and the Japanese pharmaceutical company Eisai Co. Ltd., today announced that they have signed an exclusive licence agreement for BAN2401, a novel humanized monoclonal antibody, which is being developed as a next-generation treatment for Alzheimer’s disease... [PDF] BioArctic's Press Release -

EXONHIT , A PROTOTYPE TO DETECT ALZHEIMER'S DISEASE FROM BLOOD

November 8, 2007 - ExonHit Therapeutics, a drug and diagnostic discovery company, has completed a prototype of the first blood-based Alzheimer's disease test. The company expects to have this test certified and to provide it as a service in its GLP (Good Laboratory Practices) compliant laboratories to the pharmaceutical industry as early as 2009... ExonHit's Press Release - Communiqué de Presse ExonHit -

Anavex , drug candidate for treatment of Alzheimer's disease

Nov. 28 , 2007 - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce promising developments with ANAVEX 1-41, the company's lead drug candidate for Alzheimer's disease. In recent pre-clinical animal studies, ANAVEX 1-41 prevented oxidative stress, which damages and destroys cells and is believed to be a primary cause of Alzheimer's disease. ANAVEX 1-41 also prevented the expression of caspase-3, an enzyme that plays a key role in programmed cell death and in the loss of cells in the hippocampus, the part of the brain that regulates learning, emotion and memory... Anavex' Press release -